3 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.4%) at 17,208 as of Monday, Sept. 22, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 456 issues advancing vs. 2,548 declining with 145 unchanged.

The Drugs industry currently sits down 2.1% versus the S&P 500, which is down 0.8%. On the negative front, top decliners within the industry include Intercept Pharmaceuticals ( ICPT), down 5.0%, Incyte ( INCY), down 4.3%, Illumina ( ILMN), down 2.5%, Grifols ( GRFS), down 2.2% and Alexion Pharmaceuticals ( ALXN), down 2.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry lower today. As of noon trading, AbbVie is down $0.54 (-0.9%) to $58.52 on average volume. Thus far, 4.5 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $58.42-$59.30 after having opened the day at $59.29 as compared to the previous trading day's close of $59.06.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $94.6 billion and is part of the health care sector. Shares are up 11.8% year-to-date as of the close of trading on Friday. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Pfizer ( PFE) is down $0.31 (-1.0%) to $30.09 on average volume. Thus far, 11.2 million shares of Pfizer exchanged hands as compared to its average daily volume of 22.8 million shares. The stock has ranged in price between $30.03-$30.37 after having opened the day at $30.26 as compared to the previous trading day's close of $30.40.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $193.9 billion and is part of the health care sector. Shares are down 0.8% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.92 (-0.9%) to $105.04 on average volume. Thus far, 6.6 million shares of Gilead exchanged hands as compared to its average daily volume of 13.2 million shares. The stock has ranged in price between $104.66-$107.57 after having opened the day at $106.01 as compared to the previous trading day's close of $105.96.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $160.1 billion and is part of the health care sector. Shares are up 41.1% year-to-date as of the close of trading on Friday. Currently there are 13 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

GE Beats Earnings Estimates and 4 Other Stories You Must Know Friday Morning

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

General Electric, Honeywell, Wells Fargo and Qualcomm - 5 Things You Must Know

Ericsson Rockets After Solid Q1 Following Cevian Push to Accelerate Turnaround

Ericsson Rockets After Solid Q1 Following Cevian Push to Accelerate Turnaround

Skechers Shares Are Crashing Pre-Market

Skechers Shares Are Crashing Pre-Market